Fig. 5: The m6A-modified DVL2 mRNA is stabilized by IGF2BP3 in LECs of HMC.

a Gene expressions of m6A readers in ARC and HMC (n = 8, IGF2BP1 p = 0.9988, IGF2BP2 p = 0.9972, IGF2BP3 p < 0.0001, YTHDC1 p = 0.9271, YTHDF1 p = 0.8213, YTHDF2 p = 0.0155). b IGF2BP3 protein expression in ARC and HMC (n = 3, p = 0.0363). The genes (c) and protein (d) expressions in cells treated with IGF2BP3 siRNA (n = 3, c: IGF2BP3 p = 0.0260, DVL2 p = 0.0153, d: IGF2BP3 p = 0.0193, DVL2 p = 0.0154). e Upper: Co-precipitated proteins in endogenous IGF2BP3 RIP analysis. Lower: Co-precipitated DVL2 mRNAs by IGF2BP3 antibody in RIP analysis of cells transfected with siNC or siMETTL3 #1. IgG served as the isotype control. (n = 3, all p < 0.0001). f RNA stability test. Left: The DVL2 gene expressions in each time point (n = 3, 0 h: siMETTL3 p = 0.9972, siIGF2BP3 p = 0.7163; 2 h: siMETTL3 p < 0.0001, siIGF2BP3 p = 0.0026; 4 h: siMETTL3 p < 0.0001, siIGF2BP3 p = 0.1751; 6 h: siMETTL3 p < 0.0001, siIGF2BP3 p = 0.0004; 8 h: siMETTL3 p < 0.0001, siIGF2BP3 p = 0.0005). Right: Lifespans of DVL2 mRNA. Data present are mean ± SD. The band density was normalized to loading control as a ratio for statistical analysis. Level of significance was detected using two-sided two-way ANOVA with Šídák’s multiple comparisons test (a, c–f) and unpaired Students’ t test (b). n = biological replicates, ns. = not significant, ****p < 0.0001 ***p < 0.001, **p < 0.01 and *p < 0.05.